Osteogenic changes in kidneys of hyperoxaluric rats

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 9, 2015, Pages 2000-2012

  Joshi, Sunil ^a   Clapp, William L ^a   Wang, Wei ^a   Khan, Saeed R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone morphogenetic protein; Hyperoxaluria; Matrix gla protein; Randall's plaque; Runt related transcription factor; Vimentin

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CADHERIN; COLLAGEN; CYTOKERATIN 10; CYTOKERATIN 18; CYTOKERATIN 8; FIBRONECTIN; HYDROXYPROLINE; MESSENGER RNA; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; OXALIC ACID; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HYPEROXALURIA; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE; KIDNEY TUBULE BASEMENT MEMBRANE; KIDNEY TUBULE CELL; MALE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STONE FORMATION; UPREGULATION; URINARY EXCRETION;

RATTUS;

EID: 84937459745     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.06.020     Document Type: Article

References (104)

1. Stamatelou K.K., Francis M.E., Jones C.A., Nyberg L.M., Curhan G.C. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003, 63:1817-1823.
2. Scales C.D., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States. Eur. Urol. 2012, 62:160-165.
3. Kartha G., Calle J.C., Marchini G.S., Monga M. Impact of stone disease: chronic kidney disease and quality of life. Urol. Clin. N. Am. 2013, 40:135-147.
4. Rule A.D., Roger V.L., Melton L.J., Bergstralh E.J., Li X., Peyser P.A., Krambeck A.E., Lieske J.C. Kidney stones associate with increased risk for myocardial infarction. J. Am. Soc. Nephrol. 2010, 21:1641-1644.
5. Khan S.R. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?. Urol. Res. 2012, 40:95-112.
6. Jungers P., Joly D., Barbey F., Choukroun G., Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am. J. Kidney Dis. 2004, 44:799-805.
7. Rule A.D., Bergstralh E.J., Melton L.J., Li X., Weaver A.L., Lieske J.C. Kidney stones and the risk for chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4:804-811.
8. Obligado S.H., Goldfarb D.S. The association of nephrolithiasis with hypertension and obesity: a review. Am. J. Hypertens. 2008, 21:257-264.
9. Kokorowski P.J., Routh J.C., Hubert K.C., Graham D.A., Nelson C.P. Association of urolithiasis with systemic conditions among pediatric patients at children's hospitals. J. Urol. 2012, 188:1618-1622.
10. Khan S.R., Canales B.K. Unified theory on the pathogenesis of Randall's plaques and plugs. Urolithiasis 2015, 43(Suppl. 1):109-123.
11. Randall A. The origin and growth of renal calculi. Ann. Surg. 1937, 105:1009-1027.
12. Randall A. The etiology of primary renal calculus. Int. Abstr. Surg. 1940, 71:209-240.
13. Khan S.R., Finlayson B., Hackett R. Renal papillary changes in patient with calcium oxalate lithiasis. Urology 1984, 23:194-199.
14. Linnes M.P., Krambeck A.E., Cornell L., Williams J.C., Korinek M., Bergstralh E.J., Li X., Rule A.D., McCollough C.M., Vrtiska T.J., Lieske J.C. Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int. 2013, 84:818-825.
15. Evan A.P., Lingeman J.E., Coe F.L., Parks J.H., Bledsoe S.B., Shao Y., Sommer A.J., Paterson R.F., Kuo R.L., Grynpas M. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Investig. 2003, 111:607-616.
16. Low R.K., Stoller M.L. Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J. Urol. 1997, 158:2062-2064.
17. Halperin M.L., Cheema Dhadli S., Kamel K.S. Physiology of acid-base balance: links with kidney stone prevention. Semin. Nephrol. 2006, 26:441-446.
18. Khan S.R., Glenton P.A., Backov R., Talham D.R. Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney Int. 2002, 62:2062-2072.
19. Gambaro G., D'Angelo A., Fabris A., Tosetto E., Anglani F., Lupo A. Crystals, Randall's plaques and renal stones: do bone and atherosclerosis teach us something?. J. Nephrol. 2004, 17:774-777.
20. Moe S.M., Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2008, 19:213-216.
21. Shanahan C.M. Vascular calcification. Curr. Opin. Nephrol. Hypertens. 2005, 14:361-367.
22. Briet M., Burns K.D. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin. Sci. (Lond.) 2012, 123:399-416.
23. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., Morii H., Giachelli C.M. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000, 87:E10-E17.
24. Kapustin A.N., Davies J.D., Reynolds J.L., McNair R., Jones G.T., Sidibe A., Schurgers L.J., Skepper J.N., Proudfoot D., Mayr M., Shanahan C.M. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 2011, 109:e1-e12.
25. Kapustin A.N., Shanahan C.M. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc. Med. 2012, 22:133-137.
26. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res. 2011, 109:697-711.
27. Shroff R.C., Shanahan C.M. The vascular biology of calcification. Semin. Dial. 2007, 20:103-109.
28. Jono S., Shioi A., Ikari Y., Nishizawa Y. Vascular calcification in chronic kidney disease. J. Bone Miner. Metab. 2006, 24:176-181.
29. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., McDonald J.M., Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J. Biol. Chem. 2008, 283:15319-15327.
30. Sun Y., Byon C.H., Yuan K., Chen J., Mao X., Heath J.M., Javed A., Zhang K., Anderson P.G., Chen Y. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 2012, 111:543-552.
31. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
32. Kern B., Shen J., Starbuck M., Karsenty G. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J. Biol. Chem. 2001, 276:7101-7107.
33. Zhu F., Friedman M.S., Luo W., Woolf P., Hankenson K.D. The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation. J. Cell. Physiol. 2012, 227:2677-2685.
34. Hartigan N., Garrigue-Antar L., Kadler K.E. Bone morphogenetic protein-1 (BMP-1). Identification of the minimal domain structure for procollagen C-proteinase activity. J. Biol. Chem. 2003, 278:18045-18049.
35. Roberts K.E., McElroy J.J., Wong W.P., Yen E., Widlitz A., Barst R.J., Knowles J.A., Morse J.H. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J. 2004, 24:371-374.
36. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., Smith E., Bonadio J., Goldstein S., Gundberg C., Bradley A., Karsenty G. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382:448-452.
37. Sun H., Ye F., Wang J., Shi Y., Tu Z., Bao J., Qin M., Bu H., Li Y. The upregulation of osteoblast marker genes in mesenchymal stem cells prove the osteoinductivity of hydroxyapatite/tricalcium phosphate biomaterial. Transplant. Proc. 2008, 40:2645-2648.
38. Jundt G., Berghauser K.H., Termine J.D., Schulz A. Osteonectin-a differentiation marker of bone cells. Cell Tissue Res. 1987, 248:409-415.
39. Wesson J.A., Johnson R.J., Mazzali M., Beshensky A.M., Stietz S., Giachelli C., Liaw L., Alpers C.E., Couser W.G., Kleinman J.G., Hughes J. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 2003, 14:139-147.
40. Wan M., Shi X., Feng X., Cao X. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. J. Biol. Chem. 2001, 276:10119-10125.
41. Chen X., Whitney E.M., Gao S.Y., Yang V.W. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J. Mol. Biol. 2003, 326:665-677.
42. Juliano R.L. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu. Rev. Pharmacol. Toxicol. 2002, 42:283-323.
43. Alves R.D., Eijken M., Swagemakers S., Chiba H., Titulaer M.K., Burgers P.C., Luider T.M., van Leeuwen J.P. Proteomic analysis of human osteoblastic cells: relevant proteins and functional categories for differentiation. J. Proteome Res. 2010, 9:4688-4700.
44. Challa A.A., Stefanovic B. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol. Cell. Biol. 2011, 31:3773-3789.
45. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
46. Matsubara T., Kida K., Yamaguchi A., Hata K., Ichida F., Meguro H., Aburatani H., Nishimura R., Yoneda T. BMP2 regulates osterix through Msx2 and Runx2 during osteoblast differentiation. J. Biol. Chem. 2008, 283:29119-29125.
47. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
48. Habibovic P., Bassett D.C., Doillon C.J., Gerard C., McKee M.D., Barralet J.E. Collagen biomineralization in vivo by sustained release of inorganic phosphate ions. Adv. Mater. 2010, 22:1858-1862.
49. Murshed M., McKee M.D. Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr. Opin. Nephrol. Hypertens. 2010, 19:359-365.
50. Khan S.R., Rodriguez D.E., Gower L.B., Monga M. Association of Randall plaque with collagen fibers and membrane vesicles. J. Urol. 2012, 187:1094-1100.
51. Lomashvili K.A., Cobbs S., Hennigar R.A., Hardcastle K.I., O'Neill W.C. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J. Am. Soc. Nephrol. 2004, 15:1392-1401.
52. Lomashvili K.A., Garg P., Narisawa S., Millan J.L., O'Neill W.C. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008, 73:1024-1030.
53. Liu T.M., Lee E.H. Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng. B Rev. 2013, 19:254-263.
54. Liu W., Toyosawa S., Furuichi T., Kanatani N., Yoshida C., Liu Y., Himeno M., Narai S., Yamaguchi A., Komori T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 2001, 155:157-166.
55. Khan S.R., Glenton P.A., Byer K.J. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int. 2006, 70:914-923.
56. Zuo J., Khan A., Glenton P.A., Khan S.R. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-l-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol. Dial. Transplant. 2011, 26:1785-1796.
57. Joshi S., Saylor B.T., Wang W., Peck A.B., Khan S.R. Apocynin-treatment reverses hyperoxaluria induced changes in NADPH oxidase system expression in rat kidneys: a transcriptional study. PLoS One 2012, 7:e47738.
58. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
59. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
60. Khan S.R. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J. Urol. 2013, 189:803-811.
61. Evan A.P., Lingeman J.E., Coe F.L., Parks J.H., Bledsoe S.B., Shao Y., Sommer A.J., Paterson R.F., Kuo R.L., Grynpas M. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 2003, 111:607-616.
62. Stoller M.L., Meng M.V., Abrahams H.M., Kane J.P. The primary stone event: a new hypothesis involving a vascular etiology. J. Urol. 2004, 171:1920-1924.
63. Ando R., Nagaya T., Suzuki S., Takahashi H., Kawai M., Okada A., Yasui T., Kubota Y., Umemoto Y., Tozawa K., Kohri K. Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men. J. Urol. 2013, 189:1340-1346.
64. Bagga H.S., Chi T., Miller J., Stoller M.L. New insights into the pathogenesis of renal calculi. Urol. Clin. N. Am. 2013, 40:1-12.
65. Zhu D., Mackenzie N.C., Shanahan C.M., Shroff R.C., Farquharson C., MacRae V.E. BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway. J. Cell. Mol. Med. 2015, 19:165-174.
66. Wu X.R. Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques. Urolithiasis 2015, 43(Suppl. 1):65-76.
67. de Water R., Leenen P.J., Noordermeer C., Nigg A.L., Houtsmuller A.B., Kok D.J., Schroder F.H. Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am. J. Kidney Dis. 2001, 38:331-338.
68. de Water R., Noordermeer C., Houtsmuller A.B., Nigg A.L., Stijnen T., Schroder F.H., Kok D.J. Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am. J. Kidney Dis. 2000, 36:615-625.
69. Khan S.R., Shevock P.N., Hackett R.L. Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J. Urol. 1992, 147:226-230.
70. McKee M.D., Nanci A., Khan S.R. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J. Bone Miner. Res. 1995, 10:1913-1929.
71. Khan S.R. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 2004, 8:75-88.
72. Khan S.R. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol. Res. 1995, 23:71-79.
73. Koul H.K., Koul S., Fu S., Santosham V., Seikhon A., Menon M. Oxalate: from crystal formation to crystal retention. J. Am. Soc. Nephrol. 1999, 10(Suppl. 14):S417-S421.
74. Verkoelen C.F., Schepers M.S. Changing concepts in the aetiology of renal stones. Curr. Opin. Urol. 2000, 10:539-544.
75. Koul S., Khandrika L., Meacham R.B., Koul H.K. Genome wide analysis of differentially expressed genes in HK-2 cells, a line of human kidney epithelial cells in response to oxalate. PLoS One 2012, 7:e43886.
76. Lieske J.C., Deganello S., Toback F.G. Cell-crystal interactions and kidney stone formation. Nephron 1999, 81(Suppl. 1):8-17.
77. Thamilselvan S., Byer K.J., Hackett R.L., Khan S.R. Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J. Urol. 2000, 164:224-229.
78. Thamilselvan S., Hackett R.L., Khan S.R. Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J. Urol. 1997, 157:1059-1063.
79. Cao L.C., Honeyman T.W., Cooney R., Kennington L., Scheid C.R., Jonassen J.A. Mitochondrial dysfunction is a primary event in renal cell oxalate toxicity. Kidney Int. 2004, 66:1890-1900.
80. Niimi K., Yasui T., Hirose M., Hamamoto S., Itoh Y., Okada A., Kubota Y., Kojima Y., Tozawa K., Sasaki S., Hayashi Y., Kohri K. Mitochondrial permeability transition pore opening induces the initial process of renal calcium crystallization. Free Radic. Biol. Med. 2012, 52:1207-1217.
81. Khand F.D., Gordge M.P., Robertson W.G., Noronha-Dutra A.A., Hothersall J.S. Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells. Free Radic. Biol. Med. 2002, 32:1339-1350.
82. Meimaridou E., Lobos E., Hothersall J.S. Renal oxidative vulnerability due to changes in mitochondrial-glutathione and energy homeostasis in a rat model of calcium oxalate urolithiasis. Am. J. Physiol. Renal Physiol. 2006, 291:F731-F740.
83. Khan S.R., Khan A., Byer K.J. Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol. Dial. Transplant. 2011, 26:1778-1785.
84. Thamilselvan V., Menon M., Thamilselvan S. Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2009, 297:F1399-F1410.
85. Hammes M.S., Lieske J.C., Pawar S., Spargo B.H., Toback F.G. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995, 48:501-509.
86. Koul H., Kennington L., Honeyman T., Jonassen J., Menon M., Scheid C. Activation of c-myc gene mediates the mitogenic effects of oxalate in LLC-PK1 cells, a line of renal epithelial cells. Kidney Int. 1996, 50:1525-1530.
87. Khan S.R., Kok D.J. Modulators of urinary stone formation. Front. Biosci. 2004, 9:1450-1482.
88. Khan S.R., Joshi S., Wang W., Peck A.B. Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. Am. J. Physiol. Renal Physiol. 2014, 306:F1285-F1295.
89. Miyazawa K., Aihara K., Ikeda R., Moriyama M.T., Suzuki K. cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals. Urol. Res. 2009, 37:27-33.
90. Chen N.X., Moe S.M. Vascular calcification: pathophysiology and risk factors. Curr. Hypertens. Rep. 2012, 14:228-237.
91. Smith N., Dong Y., Lian J.B., Pratap J., Kingsley P.D., van Wijnen A.J., Stein J.L., Schwarz E.M., O'Keefe R.J., Stein G.S., Drissi M.H. Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development. J. Cell. Physiol. 2005, 203:133-143.
92. Lee K.S., Kim H.J., Li Q.L., Chi X.Z., Ueta C., Komori T., Wozney J.M., Kim E.G., Choi J.Y., Ryoo H.M., Bae S.C. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol. Cell. Biol. 2000, 20:8783-8792.
93. Yang X., Meng X., Su X., Mauchley D.C., Ao L., Cleveland J.C., Fullerton D.A. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. J. Thorac. Cardiovasc. Surg. 2009, 138:1008-1015.
94. Kawata T., Nagano N., Obi M., Miyata S., Koyama C., Kobayashi N., Wakita S., Wada M. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int. 2008, 74:1270-1277.
95. Zhang C. Transcriptional regulation of bone formation by the osteoblast-specific transcription factor Osx. J. Orthop. Surg. Res. 2010, 5:37.
96. Mizuhashi K., Kanamoto T., Ito M., Moriishi T., Muranishi Y., Omori Y., Terada K., Komori T., Furukawa T. OBIF, an osteoblast induction factor, plays an essential role in bone formation in association with osteoblastogenesis. Develop. Growth Differ. 2012, 54:474-480.
97. Jang W.G., Kim E.J., Kim D.K., Ryoo H.M., Lee K.B., Kim S.H., Choi H.S., Koh J.T. BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. J. Biol. Chem. 2012, 287:905-915.
98. Mandal C.C., Ganapathy S., Gorin Y., Mahadev K., Block K., Abboud H.E., Harris S.E., Ghosh-Choudhury G., Ghosh-Choudhury N. Reactive oxygen species derived from Nox4 mediate BMP2 gene transcription and osteoblast differentiation. Biochem. J. 2011, 433:393-402.
99. Jia Z., Wang S., Tang J., He D., Cui L., Liu Z., Guo B., Huang L., Lu Y., Hu H. Does crystal deposition in genetic hypercalciuric rat kidney tissue share similarities with bone formation?. Urology 2014, 83:509. (e507-514).
100. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 2004, 15:1-12.
101. Wang W., Li C., Pang L., Shi C., Guo F., Chen A., Cao X., Wan M. Mesenchymal stem cells recruited by active TGFbeta contribute to osteogenic vascular calcification. Stem Cells Dev. 2014, 23:1392-1404.
102. Khan S.R. Animal models of kidney stone formation: an analysis. World J. Urol. 1997, 15:236-243.
103. Khan S.R. Nephrocalcinosis in animal models with and without stones. Urol. Res. 2010, 38:429-438.
104. Kumar V., Farell G., Yu S., Harrington S., Fitzpatrick L., Rzewuska E., Miller V.M., Lieske J.C. Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J. Investig. Med. 2006, 54:412-424.